Aktuelle Ernährungsmedizin , Thieme Verlag Heft 2-2024, Jahrgang 49) ISSN 0341-0501 Seite(n) 156 bis 172 DOI: 10.1055/a-2258-8105 CareLit-Dokument-Nr: 318600 |
|
SIBO (Small Intestinal Bacterial Overgrowth) ist durch eine bakterielle Überwucherung oder Fehlbesiedlung des Dünndarms in Kombination mit intestinalen Symptomen definiert. Intestinale Stase, Hypochlorhydrie, Immundefizienz, Alter u.a. sind auslösende Faktoren. Die Therapie beinhaltet die Behandlung der auslösenden Grunderkrankung, den Ausgleich einer Mangelernährung, den Einsatz von Antibiotika und Probiotika sowie diätetische Maßnahmen. Abstract Bacterial overgrowth of the small intestine (SIBO) is defined as the presence of excessive numbers of bacteria causing gastrointestinal symptoms such as bloating, nausea, abdominal pain, diarrhea and malabsorption. Diagnosis is made through cultural detection of bacteria from small intestinal aspirates or indirectly through breath tests, which can detect the bacterial fermentation products hydrogen (H2) and methane (CH4) in exhaled air after carbohydrate provocation. SIBO can be caused by various mechanisms such as reduced intestinal motility, altered gastrointestinal anatomy, reduced gastric acid or pancreatic enzyme production, altered bile acid metabolism, or immune defects. Accordingly, SIBO often develops secondary to different underlying diseases such as blind loop syndromes, gastrointestinal motility disorders including scleroderma and several neurological diseases, several chronic diseases of the gut, liver and pancreas including irritable bowel syndrome and others. Symptoms are triggered by direct bacteria-induced damage of the intestinal barrier or by bacterial metabolism such as the fermentation of dietary carbohydrates with increased gas production. The therapy includes the treatment of the underlying disease to eliminate the causal factors as much as possible, compensation for micro- and macronutrient deficiencies and treatment with antibiotics. Moreover, probiotics and dietetic therapy such as a low FODMAP diet should be considered. Recurrences are common and may necessitate repeated therapy. This review summarizes the current knowledge on SIBO pathophysiology, prevalence, diagnosis, and treatment. Zusammenfassung Unter bakterieller Fehlbesiedlung des Dünndarms (SIBO) versteht man das Vorhandensein einer übermäßigen Anzahl von Bakterien, die gastrointestinale Symptome, wie Blähungen, Nausea, abdominelle Schmerzen, Diarrhöen und Malabsorption verursachen. Die Diagnose erfolgt durch einen kulturellen Nachweis von Bakterien aus Dünndarmaspiraten oder indirekt durch Atemteste (AT), welche nach Kohlenhydratprovokation die bakteriellen Fermentationsprodukte Wasserstoff (H2) und Methan (CH4) in der Ausatemluft nachweisen können. SIBO kann durch verschiedene Mechanismen verursacht werden, wie z. B. eine verminderte Darmmotilität, eine veränderte Magen-Darm-Anatomie, eine verminderte Produktion von Magensäure oder Pankreasenzymen, einen veränderten Gallensäurestoffwechsel oder Immundefekte. Dementsprechend entwickelt sich SIBO häufig sekundär zu verschiedenen Grunderkrankungen wie Blind-Loop-Syndromen, gastrointestinalen Motilitätsstörungen einschließlich Sklerodermie und verschiedenen neurologischen Erkrankungen, mehreren chronischen Erkrankungen des Darms, der Leber und der Bauchspeicheldrüse einschließlich Reizdarmsyndrom und anderen. Symptome werden durch eine direkte bakterielle Schädigung der Darmbarriere oder durch den bakteriellen Stoffwechsel wie z.B. der Fermentation von Nahrungskohlenhydraten mit erhöhter Gasproduktion ausgelöst. Die Therapie beinhaltet die Behandlung der Grunderkrankung zur weitestgehenden Beseitigung der ursächlichen Faktoren, der Ausgleich von Mikro- und Makronährstoffdefiziten sowie die Behandlung mit Antibiotika. Darüber hinaus sollten Probiotika und diätetische Therapien wie eine Low-FODMAP-Diät in Betracht gezogen werden. Rezidive sind häufig und können eine wiederholte Therapie erforderlich machen. Diese Übersicht fasst den aktuellen Wissensstand zur Pathophysiologie, Prävalenz, Diagnose und Behandlung von SIBO zusammen. Schlüsselwörter bakterielle Fehlbesiedlung des Dünndarms - SIBO - Malabsorption - Diarrhö - Reizdarmsyndrom Key words small intestinal bacterial overgrowth - SIBO - malabsorption - diarrhea - irritable bowel syndrome 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany Literatur 1 Sroka N, Rydzewska-RosoÅowska A, Kakareko K. et al. Show Me What You Have Inside — The Complex Interplay between SIBO and Multiple Medical Conditions — A systematic Review. Nutrients 2023; 15: 90 DOI: 10.3390/nu15010090. CrossrefPubMedGoogle Scholar 2 Tansel A, Levinthal DJ. Understanding Our Tests: Hydrogen-Methane Breath Testing To Diagnose Small Intestinal Bacterial Overgrowth. Clin Transl Gastroenterol 2023; 14: e00567 DOI: 10.14309/ctg.0000000000000567. CrossrefPubMedGoogle Scholar 3 Bushyhead D, Quigley EMM. Small Intestinal Bacterial Overgrowth—Pathophysiology and Its Implications for Definition and Management. Gastroenterology 2022; 163: 593-607 DOI: 10.1053/j.gastro.2022.04.002. CrossrefPubMedGoogle Scholar 4 Pimentel M, Saad RJ, Long MD. et al. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol 2020; 115: 165-178 DOI: 10.14309/ajg.0000000000000501. CrossrefPubMedGoogle Scholar 5 Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology 2020; 159: 1526-1532 DOI: 10.1053/j.gastro.2020.06.090. CrossrefPubMedGoogle Scholar 6 Lappinga PJ, Abraham SC, Murray JA. et al. Small intestinal bacterial overgrowth: histopathologic features and clinical correlates in an underrecognized entity. Arch Pathol Lab Med 2010; 134: 264-270 DOI: 10.5858/134.2.264. CrossrefPubMedGoogle Scholar 7 Losurdo G, Leandro G, Ierardi E. et al. Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. J Neurogastroenterol Motil 2020; 26: 16-28 DOI: 10.5056/jnm19113. CrossrefPubMedGoogle Scholar 8 Ghoshal UC, Sachdeva S, Ghoshal U. et al. Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association. Indian J Gastroenterol 2022; 41: 483-507 DOI: 10.1007/s12664-022-01292-x. CrossrefPubMedGoogle Scholar 9 Karunaratne TB, Sharma A, Rao SSC. Small-bowel aspiration during upper esophagogastroduodenoscopy: Rao technique. VideoGIE 2021; 6: 152-154 DOI: 10.1016/j.vgie.2020.11.008. CrossrefPubMedGoogle Scholar 10 Hammer HF, Fox MR, Keller J. et al. European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Mot. United Eur Gastroenterol J 2021; 10: 15-40 DOI: 10.1002/ueg2.12133. CrossrefPubMedGoogle Scholar 11 Villanueva-Millan MJ, Leite G, Wang J. et al. Methanogens and Hydrogen Sulfide Producing Bacteria Guide Distinct Gut Microbe Profiles and Irritable Bowel Syndrome Subtypes. Am J Gastroenterol 2022; 117: 2055-2066 DOI: 10.14309/ajg.0000000000001997. CrossrefPubMedGoogle Scholar 12 Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy. Gut Liver 2017; 11: 196-208 DOI: 10.5009/gnl16126. CrossrefPubMedGoogle Scholar 13 Lin EC, Massey BT. Scintigraphy Demonstrates High Rate of False-positive Results from Glucose Breath Tests for Small Bowel Bacterial Overgrowth. Clin Gastroenterol Hepatol 2016; 14: 203-208 DOI: 10.1016/j.cgh.2015.07.032. CrossrefPubMedGoogle Scholar 14 Barlow JT, Leite G, Romano AE. et al. Quantitative sequencing clarifies the role of disruptor taxa, oral microbiota, and strict anaerobes in the human small-intestine microbiome. Microbiome 2021; 9: 1-17 DOI: 10.1186/s40168-021-01162-2. CrossrefPubMedGoogle Scholar 15 Ringel-Kulka T, Choi CH, Temas D. et al. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol 2015; 110: 1339-1346 DOI: 10.1038/ajg.2015.220. CrossrefPubMedGoogle Scholar 16 Gatta L, Scarpignato C, McCallum RW. et al. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017; 45: 604-616 DOI: 10.1111/apt.13928. CrossrefPubMedGoogle Scholar 17 Rezaie A, Heimanson Z, McCallum R. et al. Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol 2019; 114: 1886-1893 DOI: 10.14309/ajg.0000000000000444. CrossrefPubMedGoogle Scholar 18 Andreyev D, Jervoise P. Management of difficult-to-treat small-intestinal bacterial overgrowth. Br Soc Gastroenterol. 2021 Im Internet: https://www.bsg.org.uk/web-education-articles-list/management-of-difficult-to-treat-small-intestinal-bacterial-overgrowth-dr-andreyev-and-dr-poon-highlight-a-case-study-on-a-difficult-case-of-sibo/ PubMedGoogle Scholar 19 Lauritano EC, Gabrielli M, Scarpellini E. et al. Antibiotic therapy in small intestinal bacterial overgrowth: Rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; 13: 111-116 PubMedGoogle Scholar 20 Di Stefano M, Malservisi S, Veneto G. et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 551-556 DOI: 10.1046/j.1365-2036.2000.00751.x. CrossrefPubMedGoogle Scholar 21 Low K, Hwang L, Hua J. et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol 2010; 44: 547-550 DOI: 10.1097/MCG.0b013e3181c64c90. CrossrefPubMedGoogle Scholar 22 Lauritano EC, Gabrielli M, Scarpellini E. et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008; 103: 2031-2035 DOI: 10.1111/j.1572-0241.2008.02030.x. CrossrefPubMedGoogle Scholar 23 Lembo A, Pimentel M, Rao SS. et al. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology 2016; 151: 1113-1121 DOI: 10.1053/j.gastro.2016.08.003. CrossrefPubMedGoogle Scholar 24 Ponziani FR, Pecere S, Lopetuso L. et al. Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. Expert Opin Drug Saf 2016; 15: 983-991 DOI: 10.1080/14740338.2016.1186639. CrossrefPubMedGoogle Scholar 25 Richard N, Desprez C, Wuestenberghs F. et al. The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth. United Eur Gastroenterol J 2021; 9: 645-654 DOI: 10.1002/ueg2.12116. CrossrefPubMedGoogle Scholar 26 Malik BA, Xie YY, Wine E. et al. Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. Can J Gastroenterol 2011; 25: 41-45 DOI: 10.1155/2011/604643. CrossrefPubMedGoogle Scholar 27 Zhong C, Qu C, Wang B. et al. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth. J Clin Gastroenterol 2017; 51: 300-311 DOI: 10.1097/MCG.0000000000000814. CrossrefPubMedGoogle Scholar 28 Pimentel M, Constantino T, Kong Y. et al. A 14-Day Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath Test. Dig Dis Sci 2004; 49: 73-77 DOI: 10.1023/B:DDAS.0000011605.43979.e1. CrossrefPubMedGoogle Scholar 29 Dionne J, Ford AC, Yuan Y. et al. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol 2018; 113: 1290-1300 DOI: 10.1038/s41395-018-0195-4. CrossrefPubMedGoogle Scholar 30 Xu F, Li N, Wang C. et al. Clinical efficacy of fecal microbiota transplantation for patients with small intestinal bacterial overgrowth: a randomized, placebo-controlled clinic study. BMC Gastroenterol 2021; 21: 1-10 DOI: 10.1186/s12876-021-01630-x. CrossrefPubMedGoogle Scholar
{{detailinfo.data.api.data.document[0].apa}}
{{detailinfo.data.api.data.document[0].vancouver}}
{{detailinfo.data.api.data.document[0].harvard}}